Identify opportunities as early as possible and stay ahead of the competition by keeping a close eye on the rapidly changing generics industry.
In The future of the generics landscape report, Clarivate analysts have identified six brands losing exclusivity in 2021 and beyond. Patent expirations of these specialty drugs and biologics offer potentially substantial cost savings to patients and payers.
The report includes a section highlighting antineoplastics landscape with several brands expected to lose exclusivity during 2021-2026.
Download the report now to see which drugs and biologics made the list.
Access our global intelligence, advanced analytics and global team of experts.